Lorlatinib for Previously Treated ALK-positive Advanced Non-small-cell Lung Cancer [ID1338]

Robertson, C., Fielding, S., Walker, A., Kopasker, D. , Vadiveloo, T., Manson, P., Price, G., Brazzelli, M. and Scotland, G. (2020) Lorlatinib for Previously Treated ALK-positive Advanced Non-small-cell Lung Cancer [ID1338]. Other. Aberdeen HTA Group.

Full text not currently available from Enlighten.

Publisher's URL: https://www.nice.org.uk/guidance/ta628/evidence

Abstract

No abstract available.

Item Type:Research Reports or Papers (Other)
Additional Information:NICE Single Technology Appraisal.
Status:Published
Glasgow Author(s) Enlighten ID:Kopasker, Dr Daniel
Authors: Robertson, C., Fielding, S., Walker, A., Kopasker, D., Vadiveloo, T., Manson, P., Price, G., Brazzelli, M., and Scotland, G.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > MRC/CSO SPHSU
Publisher:Aberdeen HTA Group
Published Online:13 May 2020

University Staff: Request a correction | Enlighten Editors: Update this record